Cerence and Samsung reach cross-license agreement, Samsung to pay $49.5 million

Blackstone-backed Fortrex has successfully reached a restructuring agreement, allowing lenders to take control of the struggling food sanitation cleaner. This move is seen as a positive step towards stabilizing the company's operations.

The Supreme Court may soon overturn Trump's tariffs, potentially benefiting major companies like Target, Samsung, and Walmart. This decision could lead to significant tariff refunds for these businesses, while consumers might also have the opportunity to seek compensation for price hikes.

Samsung has been dealt a significant blow in a recent OLED patent trial, with a US jury awarding $191.4 million in damages against the tech giant. This verdict highlights the ongoing challenges in the competitive tech landscape, particularly in the realm of display technology. Samsung's plans to appeal the decision indicate that they are not ready to accept this outcome, which could have implications for their future innovations and market position.

Azul has successfully reached an agreement with its unsecured creditors committee as part of its Chapter 11 bankruptcy process. This development is significant as it indicates progress in the airline's efforts to restructure its debts and emerge stronger from bankruptcy. The agreement could pave the way for a more stable financial future for Azul, benefiting both the company and its stakeholders.

Apollo CEO Marc Rowan has reassured investors by addressing concerns regarding the health of the private-credit asset class, easing worries and highlighting the stability of the sector.

Apollo CEO Marc Rowan has reassured investors by addressing concerns regarding the health of the private-credit asset class, easing worries and highlighting the sector's resilience.

Aviat Networks reported a remarkable 21.4% increase in revenue for Q1 FY2026, surpassing market expectations. This growth highlights the company's strong performance and positive outlook in the telecommunications sector.

Stoke Therapeutics recently presented its Q3 2025 results, showcasing impressive revenue growth alongside significant advancements in its clinical programs. The company's progress highlights its commitment to developing innovative therapies, making it a key player in the biotechnology sector.

Amgen has reported a 12% increase in revenue for Q3 2025, prompting the company to raise its guidance due to strong product performance. This positive trend highlights the effectiveness of their strategies and the growing demand for their offerings.

Corsair's Q3 2025 slides indicate a strong growth trajectory, despite missing earnings forecasts. The company is navigating challenges while showcasing resilience in its performance.